Big Pharma's Appetite for Biologics Platforms Fuels New Company Creation
This article was originally published in Start Up
Executive Summary
With the industry on the cusp of a "me-better" era in biotherapies, Big Pharma has more incentive than ever to invest in novel platforms that can build better biologics. Start-Up profiles ArGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology
You may also be interested in...
Third Rock Leads $30 Mil. Series B For CytomX
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
Third Rock Leads $30 Mil. Series B For CytomX
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
Oligasis Inc.
Current technologies for increasing the biocompatibility of engineered antibodies, protein fragments, and other biological agents, such as PEGylation and various protein chaperones, have achieved a maximum half-life extension of about 60 to 80 hours. Frequent dose regimens remain necessary, holding back many potential products. Oligasis Inc. is developing a zwitterionic polymer structure as a conjugate it believes should increase any biological drug's half-life by as much four-fold over the current state of the art.